Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma
Latest Information Update: 24 Feb 2025
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
Most Recent Events
- 20 Mar 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2026.
- 19 Dec 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 06 Dec 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2022.